TY - JOUR
AU1 - Angelle, Jonathan
AU2 - Owen, Ryan
AU3 - Berezansky, Madison
AU4 - Kim, Edward
AB - Curr Sex Health Rep (2017) 9:74–78 DOI 10.1007/s11930-017-0105-6 MALE AND FEMALE SURGICAL INTERVENTIONS (A BURNETT AND C CARSON, SECTION EDITORS) Postmarketing Experience of Intralesional Collagenase Clostridium histolyticum (Xiaflex®) Injection in Men with Peyronie’sDisease 1 1 1 1 Jonathan W. Angelle & Ryan C. Owen & Madison Berezansky & Edward D. Kim Published online: 28 April 2017 Springer Science+Business Media, LLC 2017 Abstract the recommended abstinence period from the time of the last Purpose of Review There are limited data on postmarketing injection may be prudent with the administration of patient outcomes, as well as safety and management of com- intralesional collagenase C. histolyticum. Postmarketing effi- plications, with use of intralesional collagenase Clostridium cacy data have been consistent with phase III trials. histolyticum (Xiaflex®). This review aims to highlight recent postmarketing experiences and management concepts of intralesional collagenase C. histolyticum (Xiaflex®) use. Keywords Collagenase Clostridium histolyticum Peyronie’s . . . Recent Findings Postmarketing data may help determine disease Corporalrupture Patientsafety Magneticresonance whether the frequency of collagenase C. histolyticum-related imaging Survey corporal ruptures is similar to real-world clinical experience compared to phase III clinical trials. Additionally, corporal rup- tures have been observed outside the recommended abstinence period outlined by the Risk 
TI - Postmarketing Experience of Intralesional Collagenase Clostridium histolyticum (Xiaflex®) Injection in Men with Peyronie’s Disease
JF - Current Sexual Health Reports
DO - 10.1007/s11930-017-0105-6
DA - 2017-04-28
UR - https://www.deepdyve.com/lp/springer-journals/postmarketing-experience-of-intralesional-collagenase-clostridium-7gpbJyudtr
SP - 74
EP - 78
VL - 9
IS - 2
DP - DeepDyve
ER -